Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approaches

/PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer...

Related Keywords

Australia ,United Kingdom ,British ,Sally Dewhurst ,Rabab Nasrallah ,Peter Joyce ,Emma Johnson ,Marie Claire Peakman ,Syndicate Of Life Science Industry Investors ,Oxford Science Enterprises ,Premier Syndicate ,Life Science Industry Investors ,Pfizer Ventures ,Earlybird Venture Capital ,Andera Partners ,British Patient ,Support Advancement ,Lead Candidate ,Wolf Therapeutics ,British Patient Capital ,Wolf Therapeutic ,Grey Wolf ,Earlybird Venture ,Grey Wolf Therapeutics ,Oxford Science ,Claire Peakman ,Strategic Partners ,